Mathai Mammen, M.D., Ph.D., to Join FogPharma as Chairman, President and Chief Executive Officer
Read More
Archive for Press Releases
FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
Read More
FogPharma Announces Selection of Clinical Development Candidate Directly Targeting β-Catenin
Read More
FogPharma Expands Executive Leadership Team
Read More
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
Read More
FogPharma Appoints Dr. Barbara Weber to its Board of Directors
Read More
FogPharma Secures $66 Million Series B Financing
Read More